Quarterly ResultMay 15, 2026, 04:49 PM
Citius Oncology Q2 Net Revenue $1.7M; Secures $36.5M Financing
AI Summary
Citius Oncology reported net product revenues of $1.7 million for the second quarter of fiscal 2026 and $5.6 million for the first half, driven by the LYMPHIR launch. The company secured up to $36.5 million in debt and equity financing post-quarter end to support commercial expansion. Despite strong market access for LYMPHIR with 83% of target accounts on formulary and near 100% payer coverage, the company recorded a net loss of $26.6 million for the quarter, primarily due to a $19.7 million CMO contract cancellation charge.
Key Highlights
- Q2 2026 net product revenues were $1.7 million, with $5.6 million for the first half.
- Secured up to $36.5 million in debt and equity financing subsequent to quarter end.
- Gross profit for Q2 2026 was $1.3 million, representing an 80% margin.
- Net loss for Q2 2026 was $26.6 million, primarily due to a $19.7 million CMO contract cancellation charge.
- 83% of target accounts have added LYMPHIR to formulary or are actively reviewing it.
- Cash and cash equivalents stood at $2.6 million as of March 31, 2026.
- R&D expenses decreased to $1.1 million in Q2 2026 from $3.1 million in Q2 2025.
Price Impact
More from CTOR